O fio das notícias do Brasil

Receba as notícias no WhatsApp

Pill against Alzheimer’s cuts memory loss by 31% in study of 1,535 patients

The oral drug AR1001, from South Korea’s AriBio, was tested in 13 countries and still needs regulatory approval.

Por O Fio

This is a translation of the original article in Portuguese. Read the original (Português).

A pill called AR1001 slowed memory loss in Alzheimer’s patients in an international study. Over one year, the drug reduced memory decline by 31% among participants who were not using other treatments for the disease, according to the British newspaper The Times.

The research enrolled 1,535 patients in 13 countries, including the United Kingdom. The drug is being developed by the South Korean company AriBio. The results were presented at a conference in Boston, in the United States. The drug still awaits regulatory approval and, therefore, is not sold in any country.

What the number means

The 31% indicates a reduction in the speed of memory loss, not a halt to the disease or a recovery of what has already been lost. In practical terms, the patient who took the pill declined more slowly over one year than would have been expected without it. The benefit applies to the group that did not receive other treatments, which limits the conclusion for those already using other therapies.

Why the result stands out

The fact that it is a pill, rather than an infusion given at a health facility, is what matters most to families, health insurers and the public system. An oral treatment tends to be simpler to administer to older adults, but its cost and how it would be supplied have not yet been disclosed.

What comes next

To reach patients, AR1001 must pass review by regulatory agencies, which assess the efficacy and safety of the data. In Brazil, that evaluation falls to Anvisa, the National Health Surveillance Agency, and only after a possible registration could its incorporation into the SUS, Brazil’s public health system, or its inclusion in private health plans’ coverage lists be discussed. No timeline for this has been set.

For now, the result is a promising signal presented at a congress, which still must be scrutinized by regulators and the scientific community. For people living with the disease, the news points to a possible future, not a treatment option available today.

Reporting from The Times (p. 13, caderno nacional (Reino Unido): Remédio parecido com Viagra mostra desaceleração da perda de memória no Alzheimer).

Esta matéria reúne informações publicadas pelos veículos citados acima, com edição da redação do O Fio. Conheça nossa política editorial. Encontrou um erro? Fale com a redação.

Deixe um comentário

O seu endereço de e-mail não será publicado. Campos obrigatórios são marcados com *

Os comentários passam por moderação antes de aparecer. Seu e-mail não é publicado. Ofensas, ataques pessoais e propaganda são removidos. Veja a política de privacidade.